Why the study?
Does conivaptan improve outcomes in patients with acute and chronic heart failure?
Does conivaptan improve outcomes in patients with acute and chronic heart failure?
Conivaptan, a dual V1a and V2 receptor antagonist, shows potential as a therapeutic option for managing volume overload in acute and chronic heart failure.
Conivaptan should not yet enter heart failure practice; leaves open the need for larger randomized trials.
Heart failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin plays an important role in volume homeostasis and may contribute to this syndrome seen in heart failure patients. Recently, a number of agents have been developed that antagonize the effects of vasopressin. Conivaptan, which is a dual antagonist of the V1a and V2 receptor, has shown promise in animal studies and in small scale human trials as a potential therapeutic option for the treatment of acute and chronic heart failure. Further large studies are being conducted, which may confirm the benefits of conivaptan and other vasopressin antagonists in heart failure patients.
No takes yet. Share an insight, caveat, or question.
Schwarz et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: